Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) issued its earnings results on Thursday. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14, FiscalAI reports.
Elicio Therapeutics Price Performance
Elicio Therapeutics stock traded up $0.11 during trading hours on Friday, hitting $1.51. The stock had a trading volume of 756,123 shares, compared to its average volume of 285,067. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.77 and a quick ratio of 2.77. The stock has a market capitalization of $40.91 million, a price-to-earnings ratio of -0.81 and a beta of 1.64. Elicio Therapeutics has a 1-year low of $1.25 and a 1-year high of $16.00. The stock’s fifty day moving average is $1.91 and its two-hundred day moving average is $6.58.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Elicio Therapeutics in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Tuesday, October 27th. Wall Street Zen upgraded shares of Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, B. Riley Financial lowered their target price on shares of Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.
Read Our Latest Stock Report on Elicio Therapeutics
Elicio Therapeutics Company Profile
Elicio Therapeutics, Inc (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated.
Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.
Read More
- Five stocks we like better than Elicio Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
